Substance Effects — Differentiate effects of drugs of abuse and complementary agents on cognition and mood

Historical Context & Motivation

The study of how substances alter cognition and mood has deep historical roots, reaching back to ancient civilizations that used opium, cannabis, and alcohol for both medicinal and ritualistic purposes. However, the systematic scientific investigation of psychopharmacology—the study of how drugs affect mental processes—did not emerge as a formal discipline until the mid-twentieth century. Before that point, clinicians and researchers lacked the neurochemical frameworks needed to explain why substances produced their characteristic effects on thought, emotion, and behavior. The evolution of this field has been shaped by landmark discoveries in neuroscience, tragic episodes of widespread addiction, and a growing appreciation for the role of complementary and alternative agents in mental health treatment.

For clinicians preparing for the EPPP, the central question this content addresses is deceptively complex: how do various classes of abused substances and complementary agents differentially alter neurotransmitter activity, and what are the downstream consequences for cognition (attention, memory, executive function) and mood (euphoria, dysphoria, anxiety, emotional blunting)? Mastering this differentiation requires a working knowledge of receptor pharmacology, synaptic mechanisms, and the unique profiles of each substance class.

Core Principles of Psychoactive Substance Action

Before examining individual drug classes, it is essential to ground your understanding in several foundational principles that govern how all psychoactive substances operate. These principles recur across every drug category you will encounter on the EPPP, and they provide the mechanistic logic that allows you to predict a substance's effects on cognition and mood even when you encounter an unfamiliar compound.

Visual Map: Neurotransmitter Systems and Drug Targets

The diagram above illustrates a crucial organizing principle for the EPPP: although each drug class has a distinct primary mechanism, the downstream effect on the mesolimbic dopamine pathway is the shared basis for their reinforcing—and often addictive—properties. Notice that the dopamine system box contains the most direct-acting substances (cocaine, amphetamines), while the GABA system represents drugs whose cognitive effects (sedation, amnesia, impaired executive function) are mediated through inhibitory neurotransmission. The serotonin system is notable because it is targeted both by classic hallucinogens (LSD, psilocybin) and by the complementary agent St. John's wort, which increases serotonergic tone through a mechanism partially analogous to SSRIs. Understanding which system a substance targets allows you to predict its cognitive and mood profile with considerable accuracy.

Mechanisms of Action: How Substances Alter Cognition and Mood

Stimulants: Cocaine and Amphetamines

Cocaine blocks the dopamine transporter (DAT), the norepinephrine transporter (NET), and the serotonin transporter (SERT), preventing reuptake and flooding the synapse with these monoamines. The acute cognitive effects include heightened alertness, increased confidence, and a subjective sense of mental clarity, while mood effects center on intense euphoria followed by a characteristic crash characterized by dysphoria, anhedonia, and fatigue. Amphetamines differ mechanistically by not merely blocking DAT but actually reversing its function, causing dopamine to flow out of the presynaptic terminal into the synapse. Amphetamines also promote vesicular release and inhibit monoamine oxidase (MAO). Chronic use of either substance produces cognitive deficits in attention, working memory, and decision-making, alongside persistent mood disturbances including irritability, paranoia, and stimulant-induced psychosis resembling the positive symptoms of schizophrenia.

Depressants: Alcohol, Benzodiazepines, and Barbiturates

Alcohol has a dual mechanism: it enhances GABAergic inhibition (increasing chloride conductance at GABA-A receptors) while simultaneously antagonizing glutamatergic excitation (blocking NMDA receptors). This combined effect produces dose-dependent cognitive impairment: at low doses, mild disinhibition and impaired judgment; at moderate doses, slowed reaction time, compromised attention, and anterograde amnesia ("blackouts"); at high doses, stupor and potentially fatal respiratory depression. Mood effects include initial anxiolysis and social facilitation followed by emotional lability, aggression, or depressive affect. Benzodiazepines act as positive allosteric modulators (PAMs) at GABA-A receptors, increasing the frequency of chloride channel opening. They produce anxiolysis, sedation, and anterograde amnesia but carry lower overdose risk than barbiturates. Barbiturates increase the duration of chloride channel opening and can directly activate the channel at high doses, which accounts for their greater lethality in overdose.

Opioids: Heroin, Prescription Analgesics, and Fentanyl

Opioids bind primarily to mu (μ) opioid receptors located throughout the central nervous system. In the VTA, opioid agonism inhibits GABAergic interneurons that normally suppress dopamine neurons, producing a disinhibition of dopamine release—an indirect mechanism of reward. Cognitively, opioids induce sedation, impair concentration, slow psychomotor processing, and compromise new memory formation. The mood profile is dominated by intense euphoria and emotional analgesia acutely, transitioning to profound dysphoria, anxiety, and irritability during withdrawal. Chronic opioid use is associated with cognitive rigidity, impaired emotional regulation, and reduced sensitivity to natural rewards—a phenomenon called reward deficiency.

Hallucinogens and Cannabis

Classic hallucinogens such as LSD and psilocybin are agonists at the serotonin 5-HT₂A receptor, particularly in the prefrontal cortex. They produce dramatic perceptual distortions, synesthesia, altered sense of time, and loosening of associative thinking. Mood effects range from mystical-type experiences and profound awe to anxiety-laden "bad trips" with paranoia. Cannabis acts primarily through THC binding to CB₁ receptors in the hippocampus, prefrontal cortex, basal ganglia, and cerebellum. Cognitive effects include impaired short-term memory encoding, diminished attention, and slowed information processing. Mood effects are typically euphoria and relaxation at moderate doses, but high-potency products or vulnerable individuals may experience anxiety, paranoia, or cannabis-induced psychosis. The cannabinoid CBD (cannabidiol) does not produce intoxication and is being investigated as a complementary agent for anxiety and psychosis.

Detailed Classification: Drugs of Abuse vs. Complementary Agents

A critical EPPP competency is distinguishing between drugs of abuse and complementary agents—substances used as adjuncts or alternatives to conventional psychopharmacological treatments. While drugs of abuse typically produce rapid, intense alterations in mood and cognition via high-efficacy receptor activation and robust dopamine surges, complementary agents generally exert subtler, more gradual effects on the same neurotransmitter systems. The table below systematically compares the major categories.

Worked Example: Clinical Vignette Analysis

EPPP questions frequently present a clinical vignette and ask you to identify the most likely substance involved based on its cognitive and mood effects. The following worked example walks through the reasoning process step by step.

Drugs of Abuse vs. Complementary Agents: Strengths and Limitations

The EPPP expects candidates to appreciate that complementary agents and drugs of abuse, while sometimes acting on overlapping neurotransmitter systems, differ profoundly in their therapeutic utility, abuse potential, and risk profiles. The following table highlights the key dimensions of comparison that are most likely to be tested.

Connections to Advanced Theory: Neuroplasticity, Allostatic Load, and Psychedelic-Assisted Therapy

The foundation you have built in this lesson connects directly to several advanced theoretical frameworks that are increasingly represented in the research literature and, by extension, on the EPPP. Understanding substance effects on cognition and mood at the receptor level is necessary but not sufficient; contemporary neuroscience emphasizes the role of neuroplasticity, allostatic load theory, and emerging psychedelic-assisted therapeutic paradigms as extensions of these foundational concepts.

As you advance in your study of biological bases of behavior, remember that the receptor-level knowledge covered here serves as the mechanistic foundation upon which these more complex models are built. Koob's allostatic load model, for example, cannot be understood without first grasping how chronic opioid use downregulates mu receptors and depletes endogenous endorphins, or how chronic stimulant use reduces dopamine receptor density in the striatum. Similarly, the therapeutic potential of psilocybin makes no sense without understanding its primary action at 5-HT₂A receptors and the resulting modulation of default mode network connectivity.

Practice Problems

Lesson Summary